Literature DB >> 11711691

Drug interactions update: drugs, herbs, and oral anticoagulation.

A K Wittkowsky1.   

Abstract

Management of warfarin drug interactions is often complicated by lack of information regarding interactions with new drugs and with herbal medicinals. The pharmaceutical industry has increased both the number and quality of drug interaction studies prior to marketing new agents. Interactions may still occur in patients, however, despite negative pre-marketing studies in healthy volunteers. The clinical significance and intensity of warfarin interactions with prescription drugs (e.g., celecoxib, proton pump inhibitors, and selective serotonin reuptake inhibitors) can often be predicted on the basis of known metabolic characteristics of the drugs and warfarin enantiomers. Drug interactions with herbal medicinals are much more difficult to characterize and predict because of the lack of federal regulations regarding safety, efficacy, and manufacturing standards. Published case reports of interactions between warfarin and even the most widely used herbal medicinals are limited. Practitioners are encouraged to report such interactions through the FDA MedWatch program.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11711691     DOI: 10.1023/a:1012742628628

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  21 in total

Review 1.  Safety issues with herbal medicine.

Authors:  J I Boullata; A M Nace
Journal:  Pharmacotherapy       Date:  2000-03       Impact factor: 4.705

2.  In vivo drug-drug interaction studies--a survey of all new molecular entities approved from 1987 to 1997.

Authors:  P J Marroum; R S Uppoor; T Parmelee; F Ajayi; A Burnett; R Yuan; R Svadjian; L J Lesko; J D Balian
Journal:  Clin Pharmacol Ther       Date:  2000-09       Impact factor: 6.875

3.  Unsafe and potentially safe herbal therapies.

Authors:  T B Klepser; M E Klepser
Journal:  Am J Health Syst Pharm       Date:  1999-01-15       Impact factor: 2.637

Review 4.  Antidepressant interactions with warfarin.

Authors:  D Duncan; K Sayal; H McConnell; D Taylor
Journal:  Int Clin Psychopharmacol       Date:  1998-03       Impact factor: 1.659

5.  Probable interaction between warfarin and ginseng.

Authors:  K Janetzky; A P Morreale
Journal:  Am J Health Syst Pharm       Date:  1997-03-15       Impact factor: 2.637

Review 6.  White paper on herbal products. American College of Clinical Pharmacy.

Authors:  L G Miller; A Hume; I M Harris; E A Jackson; T J Kanmaz; J S Cauffield; T W Chin; M Knell
Journal:  Pharmacotherapy       Date:  2000-07       Impact factor: 4.705

Review 7.  Inhibitors of Cytochrome P-450s and their mechanism of action.

Authors:  B Testa; P Jenner
Journal:  Drug Metab Rev       Date:  1981       Impact factor: 4.518

8.  Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey.

Authors:  D M Eisenberg; R B Davis; S L Ettner; S Appel; S Wilkey; M Van Rompay; R C Kessler
Journal:  JAMA       Date:  1998-11-11       Impact factor: 56.272

Review 9.  Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.

Authors:  T Andersson
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

10.  Evaluation of commercial ginseng products.

Authors:  L E Liberti; A Der Marderosian
Journal:  J Pharm Sci       Date:  1978-10       Impact factor: 3.534

View more
  9 in total

Review 1.  Best practice in primary care pathology: review 8.

Authors:  W S A Smellie; K K Hampton; R Bowley; R Bowlees; S C Martin; N Shaw; J Hoffman; J P Ng; S M Mackenzie; C van Heyningen
Journal:  J Clin Pathol       Date:  2006-12-15       Impact factor: 3.411

Review 2.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Walter Ageno; Alexander S Gallus; Ann Wittkowsky; Mark Crowther; Elaine M Hylek; Gualtiero Palareti
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  Identification and weighting of the most critical "real-life" drug-drug interactions with acenocoumarol in a tertiary care hospital.

Authors:  L Gschwind; V Rollason; C Lovis; F Boehlen; P Bonnabry; P Dayer; J A Desmeules
Journal:  Eur J Clin Pharmacol       Date:  2012-08-19       Impact factor: 2.953

4.  Concomitant drug, dietary, and lifestyle issues in patients with atrial fibrillation receiving anticoagulation therapy for stroke prophylaxis.

Authors:  Edith A Nutescu; Cathy M Helgason
Journal:  Curr Treat Options Cardiovasc Med       Date:  2005-07

5.  Enhanced Interaction between Warfarin and High-Dose Ketoconazole: A Case Report.

Authors:  Cynthia A Jackevicius; Mannhu N Ton
Journal:  Case Rep Med       Date:  2009-12-09

6.  Gastroprotective efficacy and safety evaluation of scoparone derivatives on experimentally induced gastric lesions in rodents.

Authors:  Dong Ju Son; Gyung Rak Lee; Sungil Oh; Sung Eun Lee; Won Sik Choi
Journal:  Nutrients       Date:  2015-03-13       Impact factor: 5.717

7.  Monitoring of anticoagulant therapy in heart disease: considerations for the current assays.

Authors:  Mohammadali Boroumand; Hamidreza Goodarzynejad
Journal:  J Tehran Heart Cent       Date:  2010-05-31

8.  Long-Term Statin Administration Does Not Affect Warfarin Time in Therapeutic Range in Australia or Singapore.

Authors:  Nijole Bernaitis; Chi Keong Ching; Siew Chong Teo; Tony Badrick; Andrew K Davey; Julia Crilly; Shailendra Anoopkumar-Dukie
Journal:  J Clin Med       Date:  2018-05-01       Impact factor: 4.241

9.  Protective effects of celery juice in treatments with Doxorubicin.

Authors:  Jovanka Kolarovic; Mira Popovic; Momir Mikov; Radoslav Mitic; Ljiljana Gvozdenovic
Journal:  Molecules       Date:  2009-04-24       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.